SAMN29555033
External Id
Trioscience
INSDC center name
2022-09-01T01:35:04.237Z
INSDC first public
2022-09-01T01:35:04.237Z
INSDC last update
SRS13734924
INSDC secondary accession
live
INSDC status
Pathogen.cl
NCBI submission model
Pathogen.cl.1.0
NCBI submission package
SRS13734924
SRA accession
Bilgehan Ergan
collected_by
2020-07-29
collection_date
TMAD:A349-2020
description
Turkey:Istnabul
geo_loc_name
Homo sapiens
host
64
host_age
chemotherapy administered lung adenocarcinoma patient
host_description
C. difficile infections (CDI)
host_disease
bacterimia, pleural effusions and Acinetobacter baumannii-associated lung co-infection
host_disease_outcome
Bacteremia
host_disease_stage
Intensive Care Unit
host_health_state
female
host_sex
Blood
host_tissue_sampled
Bilgehan Ergan, Elvan Sayin
identified_at_the_species_level_by
A349-2020
isolate
Blood and Stool
isolation_source
40.886293 N 29.262607 E
lat_lon
Berkay Yekta Ekren, Ali ARSLAN
ont_library_preparation
Clostridioides difficile
http://purl.obolibrary.org/obo/NCBITaxon_1496
organism
2
passage_history
Nurver Ulger Toprak, Orhan Ozcan, Ugur Sezerman
pathogenomics_analysis
Sait Karakurt, Volkan Korten
patient_treatment
Pathogen: clinical or host-associated sample from Clostridioides difficile
title
bacteremia was treated with intravenous metronidazole (3X 500 mg), intravenous vancomycin (2X1 gr) and oral vancomycin (4X500 mg) for ten days
treatment